TP53 and diffuse large B-cell lymphoma: The negative prognostic impact of TP53 mutation and its association with drug resistance is well known in many malignancies, including DLBCL [10,15]; however, the prognostic value of TP53 mutations in refractory DLBCL patients receiving CAR T cells is still undefined.